In vitro inhibitory effects of Palonosetron Hydrochloride (cas 135729-62-3), bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum

Add time:08/16/2019    Source:sciencedirect.com

In this study, we investigated the effects of the drugs, palonosetron hydrochloride, bevacizumab and cyclophosphamide, on human serum paraoxonase-I (hPON1) enzyme activity in in vitro conditions. The enzyme was purified ∼231-fold with 34.2% yield by using ammonium sulphate precipitation, DEAE-Sephadex A-50 ion-exchange chromatography and Sephadex G-200 gel-filtration chromatography from human serum. hPON1 exhibited a single protein band on the SDS polyacrylamide gel electrophoresis. The inhibition studies were performed on paraoxonase activity of palonosetron hydrochloride, bevacizumab and cyclophosphamide. Ki constants were found as 0.033 ± 0.001, 0.054 ± 0.003 mM and 3.419 ± 0.518 mM, respectively. Compared to the inhibition rates of the drugs, palonosetron hydrochloride has the maximum inhibition rate. However, inhibition mechanisms of the drugs were determined as noncompetitive by Lineweaver-Burk curves.

We also recommend Trading Suppliers and Manufacturers of Palonosetron Hydrochloride (cas 135729-62-3). Pls Click Website Link as below: cas 135729-62-3 suppliers

Prev:Scientific ArticleThe effect of Palonosetron (cas 135729-56-5) on rocuronium-induced withdrawal movementO efeito de Palonosetron (cas 135729-56-5) sobre o movimento de retração induzido por rocurônio
Next:Original articleNeuroadaptive changes in metabotropic glutamate mGlu2/3R expression during different phases of cocaine addiction in rats)